Budget 2026 targets 4.3% fiscal deficit while inflation hits record low of 1.33%. Real GDP growth estimated at 7.4%. Structural shift to Debt-to-GDP targeting announced.
Team Sahi
Market snapshot: Prime Minister Narendra Modi's post-budget address highlighted a dual victory for the Indian economy: robust growth coupled with historic price stability. The Union Budget 2026-27 adheres strictly to fiscal consolidation, setting a fiscal deficit target of 4.3% of GDP for FY27, marginally lower than the Revised Estimate (RE) of 4.4% for FY26. This comes against a backdrop of benign inflation, with the Consumer Price Index (CPI) dropping to 1.33% in December 2025, the lowest in the current series.
Summary: Budget 2026 targets 4.3% fiscal deficit while inflation hits record low of 1.33%. Real GDP growth estimated at 7.4%. Structural shift to Debt-to-GDP targeting announced.
The government's adherence to the fiscal glide path despite global headwinds signals mature economic stewardship. The shift from pure deficit targeting to a 'Debt-to-GDP' framework (aiming for 50% by 2031) aligns India with global best practices. With inflation well below the RBI's 4% anchor, the central bank has the liquidity headroom to support credit expansion without risking price instability. The focus on capital expenditure (₹12 trillion projected) ensures the multiplier effect continues to drive the 7.4% real GDP growth.
Budget 2026-27 effectively bridges the gap between populist demand and fiscal rectitude. By leveraging the low-inflation environment to push for higher real growth, the administration creates a conducive environment for equity markets, particularly in infrastructure and consumption sectors.
High Performance Trading with SAHI.
Related
Recent
Fed's 2026 Outlook: Economic Resilience Meets Persistent Inflationary Pressures
Geopolitical Brinkmanship: Trump-Iran Tensions and the Indian Market Outlook
Zydus Lifesciences Disrupts Respiratory Care with India’s First Drug-Free Device 'Pepair' at ₹990
Infosys Pivots to 'AI-First' Era: New Framework Targets $300 Billion Market Opportunity
Zydus Lifesciences Disrupts Respiratory Care with India’s First Affordable Drug-Free Device ‘PepairTM’ at ₹990